Hepatitis B virus reverse transcriptase mutations in treatment Naïve chronic hepatitis B patients

Journal of Medical Virology

Volumn 85, Issue 7, 2013, Pages 1155-1162

  Singla, Bhupesh ^a   Chakraborti, Anuradha ^a   Sharma, Bal Krishan ^a   Kapil, Shweta ^a   Chawla, Yogesh K ^a   Arora, Sunil K ^a   Das, Ashim ^a   Dhiman, Radha K ^a   Duseja, Ajay ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Chronic hepatitis B; Genotype; Hepatitis B virus; Nucleos(t)ide analogs; Reverse transcriptase; Semi nested PCR

Indexed keywords

ANTIVIRUS AGENT; RNA DIRECTED DNA POLYMERASE;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; SEQUENCE ANALYSIS; VIRUS MUTATION;

CHRONIC HEPATITIS B; GENOTYPE; HEPATITIS B VIRUS; NUCLEOS(T)IDE ANALOGS; REVERSE TRANSCRIPTASE; SEMI-NESTED PCR;

ADULT; AMINO ACID SUBSTITUTION; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INDIA; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION, MISSENSE; PREVALENCE; RNA-DIRECTED DNA POLYMERASE; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 84878236448     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23608     Document Type: Article

References (36)

1. Aberle SW, Kletzmayr J, Watschinger B, Schmied B, Vetter N, Puchhammer-Stockl E. 2001. Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions. J Clin Microbiol 39:1972-1974.
2. Banerjee A, Chandra PK, Datta S, Biswas A, Bhattacharya P, Chakraborty S, Chakrabarti S, Bhattacharya SK, Chakravarty R. 2007. Frequency and significance of hepatitis B virus surface gene variant circulating among 'antiHBc only' individuals in Eastern India. J Clin Virol 40:312-317.
3. Bartholomeusz A, Locarnini SA. 2006. Antiviral drug drug resistance: Clinical consequences and molecular aspects. Semin Liver Dis 26:162-170.
4. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D, BEHoLD AI463022 Study Group. 2006. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354:1001-1010.
5. Ciancio A, Smedile A, Rizzetto M, Lagget M, Gerin J, Korba B. 2004. Identification of HBV DNA sequences that are predictive of response to lamivudine therapy. Hepatology 39:64-73.
6. Cooreman MP, Leroux-Roles G, Paulij WP. 2001. Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci 8:237-247.
7. Fares MA, Holmes EC. 2002. A revised evolutionary history of hepatitis B virus (HBV). J Mol Evol 54:807-814.
8. Henke-Gendo C, Amini-Bavil-Olyaee S, Challapalli D, Trautwein C, Deppe H, Schulz TF, Heim A, Tacke F. 2008. Symptomatic hepatitis B virus (HBV) reactivation despite reduced viral fitness is associated with HBV test and immune escape mutations in an HIV-coinfected patient. J Infect Dis 198:1620-1624.
9. Huang ZM, Huang QW, Qin YQ, He YZ, Qin HJ, Zhou YN, Xu X, Huang MJ. 2005. YMDD mutations in patients with chronic hepatitis B untreated with antiviral drug medicines. World J Gastroenterol 11:867-870.
10. Ismail AM, Samuel P, Eapen CE, Kannangai R, Abraham P. 2012. Antiviral drug resistance mutations and genotype-associated amino acid substitutions in treatment-naïve hepatitis B virus-infected individuals from the Indian subcontinent. Intervirology 55:36-44.
11. Kazim SN, Chauhan R, Das BC, Sarin SK. 2006. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy. J Gastroenterol Hepatol 21:1525-1532.
12. Kirschberg O, Schüttler C, Repp R, Schaefer S. 2004. A multiplex-PCR to identify hepatitis B virus-genotypes A-F. J Clin Virol 29:39-43.
13. Kumar A, Kumar SI, Pandey R, Naik S, Aggarwal R. 2005. Hepatitis B virus genotype A is more often associated with severe liver disease in northern India than is genotype D. Indian J Gastroenterol 24:19-22.
14. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, Han S, Poynard T, Myers M, Chao G, Lloyd D, Brown NA. 2005. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129:528-536.
15. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L, BEHoLD AI463027 Study Group. 2006. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354:1011-1020.
16. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA, Globe Study Group. 2007. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357:2576-2588.
17. Lampertico P, Vigano M, Yurdaydin C, Idilman R, Buti M, Esteban R, Papatheodoridis GV, Pinzello G, Vinci M, Minola E, Suter F, Del Poggio P, Andreoletti M, Fagiuoli S, Colombo AE, Salmi A, Santantonio T, Magni C, Gubertini G, Maldini FF, Terreni N, Facchetti F, Soffredini R, Colombo M. 2008. Effectiveness of entecavir for the treatment of nuc-naïve chronic hepatitis B patients: A large multicenter cohort study in clinical practice [abstract]. Hepatology 48:707A.
18. Lee CZ, Lee HS, Huang GT, Yang PM, Sheu JC. 2006. Detection of YMDD mutation using mutant-specific primers in chronic hepatitis B patients before and after lamivudine treatment. World J Gastroenterol 12:5301-5305.
19. Lim SG, Cheng Y, Guindon S, Seet BL, Lee LY, Hu P, Wasser S, Peter FJ, Tan T, Goode M, Rodrigo AG. 2007. Viral quasi-species evolution during hepatitis Be antigen seroconversion. Gastroenterology 133:951-958.
20. Liu BM, Li T, Xu J, Li XG, Dong JP, Yan P, Yang JX, Yan L, Gao ZY, Li WP, Sun XW, Wang YH, Jiao XJ, Hou CS, Zhuang H. 2010. Characterization of potential antiviral drug resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients. Antiviral drug Res 85:512-519.
21. Locarnini S. 2008. Primary resistance, multidrug resistance and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int 2:47-51.
22. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C. 2007. Antiviral drug drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. Hepatology 46:254-265.
23. Ludwig AD, Goebel T, Adams O, Baumann N, Hauck K, Fey H, Hengel H, Haussinger D, Erhardt A. 2008. Primary resistance mutations against nucleos(t)ide analogues in treatment naïve patients with HBV infection [abstract]. Hepatology 48:701A.
24. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL, Adefovir Dipivoxil 437 Study Group. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348:808-816.
25. Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, Locarnini S, Martin P, Richman DD, Zoulim F. 2008. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: Recommendations for a standardized approach. Gastroenterology 134:405-415.
26. Pollicino T, Isgro G, DiStefano R, Ferraro D, Maimone S, Brancatell S, Squadrito G, DiMarco V, Craxi A, Raimondo G. 2009. Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients. Antivi Drug Ther 14:649-654.
27. Schildgen O, Olotu C, Funk A, Zollner B, Helm M, Rockstroh JK, Sirma H. 2010. Selection and counterselection of the rtI233V adefovir resistance mutation during antiviral drug therapy. J Clin Microbiol 48:631-634.
28. Shao J, Wei L, Wang H, Sun Y, Zhang LF, Li J, Dong JQ. 2007. Relationship between hepatitis B virus DNA levels and liver histology in patients with chronic hepatitis B. World J Gastroenterol 13:2104-2107.
29. Sheldon J, Camino N, Rodés B, Bartholomeusz A, Kuiper M, Tacke F, Núñez M, Mauss S, Lutz T, Klausen G, Locarnini S, Soriano V. 2005. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 10:727-734.
30. Stanford University HBV Sequence Database [http://hivdb.stanford.edu/HBV/DB/cgi-bin/MutPrevByGenotypeRxHBV.cgi].
31. Svicher V, Gori C, Trignetti M, Visca M, Micheli V, Bernassola M, Salpini R, Gubertini G, Longo R, Niero F, Ceccherini-Silberstein F, De Sanctis GM, Spanò A, Cappiello G, Perno CF. 2009a. The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes. J Hepatol 50:461-470.
32. Svicher V, Gori C, Salpini R, Trignetti M, Romano S, Bonomini A, Rizzardini G, Ceccherini Silberstein F. 2009b. HIV-driven immune-suppression modulates HBV evolution in HBV+HIV co-infected patients. 7th European HIV Drug Resistance Workshop. Stockholm, Sweden. Abstract 37.
33. Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS. 2008. Tenofovir monotherapy is effective in hepatitis B patients with antiviral drug treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 48:391-398.
34. Vivekanandan P, Abraham P, Sridharan G, Chandy G, Daniel D, Raghuraman S, Daniel HD, Subramaniam T. 2004. Distribution of hepatitis B virus genotypes in blood donors and chronically infected patients in a tertiary care hospital in southern India. Clin Infect Dis 38:e81-e86.
35. Zheng J, Zeng Z, Zhang D, Yu Y, Wang F, Pan CQ. 2012. Prevalence and significance of Hepatitis B reverse transcriptase mutants in different disease stages of untreated patients. Liver Int 32:1535-1542.
36. Zhong Y, Lv J, Li J, Xing X, Zhu H, Su H, Chen L, Zhou X. 2012. Prevalence, virology and antiviral drug drugs susceptibility of hepatitis B virus rtN238H polymerase mutation from 1865 Chinese patients with chronic hepatitis B. Antiviral Drug Res 93:185-190.